ReviewDrug delivery and translational research2023
Fucoidan, a brown seaweed polysaccharide in nanodrug delivery.
Review in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Fucoidans: a new frontier in brown seaweed research and biotechnology.Cell surface (Amsterdam, Netherlands) · 2026Review
- Hesperetin loaded fucoidan selenium nanoparticles alleviate cisplatin induced acute kidney injury via antioxidant and cGAS STING pathway regulation.Discover nano · 2026Article
- Fucoidan Attenuates Lead-Induced Liver Injury Associated with IGFBP1 and Gut Microbiota-Derived Tryptophol Metabolism.Marine drugs · 2026Article
- Insights into the Fucoidan and Mannitol Biosynthetic Pathways in the Brown Seaweed Padina Tetrastromatica Based on Draft Genome and Transcriptome Analysis.Marine biotechnology (New York, N.Y.) · 2026Article
- Fucoidan: An Update on Function, Role in Human Health and Applications.Chemical biology & drug design · 2026Review
- Article
- Marine Algae Hydrogels as Emerging Biomaterials for Medicine.Gels (Basel, Switzerland) · 2026Review
- Engineered Marine Polysaccharide Carriers for Targeted Delivery in Diabetes Management.International journal of nanomedicine · 2026Review
- Fucoidan and alginate from brown seaweeds: extraction, structural diversity, biocompatibility, biodegradability, and biomedical applications.Frontiers in plant science · 2026Review
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach.Journal of materials science. Materials in medicine · 2025Review
- Effect of Different Freeze-Thaw Cycles and Fucoidan on Structural and Functional Properties of Lotus Seed Starch Gels: Insights from Structural Characterization andFoods (Basel, Switzerland) · 2025Article
- From Sea to Therapy: Marine Biomaterials for Drug Delivery and Wound Healing.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Fabrication of gelatine/fucoidan nanogel-coated silver nanoparticles for the treatment of wound healing therapy and nursing care.Regenerative therapy · 2025Article
- Recent biotechnological applications of value-added bioactive compounds from microalgae and seaweeds.Botanical studies · 2024Review
- The potent osteo-inductive capacity of bioinspired brown seaweed-derived carbohydrate nanofibrous three-dimensional scaffolds.Marine life science & technology · 2024Article
- Effect of Seaweed-Derived Fucoidans fromToxins · 2024Article
- Enhancement of Oral Bioavailability of Protein and Peptide by Polysaccharide-based Nanoparticles.Protein and peptide letters · 2024Review
- Cardiac tissue engineering: an emerging approach to the treatment of heart failure.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidan-a sulfated marine seaweed obtained from brown algae-has raised considerable interest in the scientific community over the last decade as it possesses a wide range of biological activities such as antioxidant, antiviral, anti-inflammatory, anticoagulant, antithrombotic, anticarcinogenic, and immunoregulatory. This polysaccharide finds application as a drug delivery vehicle due to its non-cytotoxicity, biocompatibility, and biodegradability. Besides, nano biomedical systems have used this marine alga for diagnostic and therapeutic purposes. Fucoidan has been extensively studied for use in regenerative medicines, in wound healing, and for sustained drug delivery due to its large biodiversity, cost-effectiveness, and mild procedures for extraction and purification. However, the main concern that limits its application is the variance in its batch-to-batch extraction owing to species type, harvesting, and climatic factors. The current review encloses a compendious overview of the origin, chemical structure, and physicochemical and biological properties of fucoidan and its significant role in nanodrug delivery systems. Special emphasis is given to the recent advances in the use of native/modified fucoidan, its combination with chitosan and metal ions for nanodrug delivery applications, especially in cancer treatment. Additionally, use of fucoidan in human clinical trials as a complementary therapeutic agent is also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.